Initial results of reteplase in the treatment of acute lower extremity arterial occlusions

Journal of Vascular and Interventional Radiology

Volumn 11, Issue 3, 2000, Pages 289-294

  Davidian, Mark M ^a   Powell, Alex ^a   Benenati, James F ^a   Katzen, Barry T ^a   Becker, Gary J ^a   Zemel, Gerald ^a  

^a BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

Author keywords

Peripheral arteries, stenosis or occlusion; Reteplase; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOGEN; HEPARIN; PROTHROMBIN; RETEPLASE; THROMBOPLASTIN;

ADULT; AGED; ARTERY CATHETER; ARTERY GRAFT; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FEMOROPOPLITEAL BYPASS; FIBRINOLYTIC THERAPY; HEMOPTYSIS; HUMAN; ILIAC ARTERY; LEG ANGIOGRAPHY; LEG ISCHEMIA; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE;

EID: 0034061222     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61419-5     Document Type: Article

References (34)

1. Rutherford RB, Baker DJ, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517-538.
2. Kohnert U, Rudolph R, Verheijen JH, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5:93-100.
3. Martin U, von Mollendorff E, Akpan W, et al. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemostasis 1991; 66:569-574.
4. Seifried E, Muller MM, Martin U, Konig R, Hombach V. Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction patients: pharmacokinetics and effects of the hemostatic system. Ann NY Acad Sci 1991; 667: 417-420.
5. Martin U, Bader R, Bohm E, et al. BM 06.022: a novel recombinant plasminogen activator. Cardiovasc Drug Rev 1993; 11:299-311.
6. Fischer S, Kohnert U. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis Proteolysis 1997; 11: 129-135.
7. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11:1-11.
8. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. Ann Int Med 1991; 115:256-265.
9. Bovill EG, Tracy RP, Knatterud GL, et al. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIb trial). Am J Cardiol 1997; 79:391-396
10. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91:2725-2732.
11. Bode C, Smalling RW, Gunther B, et al. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (r-PA) and front-loaded, accelerated alteplase (rt-PA) in patients with acute myocardial infarction. Circulation 1996; 94:891-898.
12. The GUSTO III investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337:1118-1123.
13. Poliwoda H, Alexander K, Buhl V, Hosten D, Wagner HH. Treatment of chronic arterial occlusions with streptokinase. N Engl J Med 1969; 280:689-692.
14. Dotter CT, Rosch J, Seaman AJ, Dennis D, Massey WH. Streptokinase treatment of thromboembolic disease. Radiology 1972; 102:283-290.
15. Katzen BT, van Breda A. Low dose streptokinase in the treatment of arterial occlusions. AJR 1981; 136: 1171-1178.
16. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. AJR 1985; 144:769-775.
17. Belkin M, Belkin B, Buchman CA, et al. Intra-arterial fibrinolytic therapy: efficacy of streptokinase vs. urokinase. Arch Surg 1986; 121:769-773.
18. Gardiner GA, Koltun W, Kandarpa K, et al. Thrombolysis of occluded femoropopliteal grafts. AJR 1986; 147:621-626.
19. van Breda A, Katzen BT, Deutsch AS. Urokinase versus streptokinase in local thrombolysis. Radiology 1987; 165:109-111.
20. Weitz JI, Byrne J, Clagett P, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94:3026-3049.
21. Graor RA, Risius B, Denny KM, et al. Local thrombolysis in the treatment of thrombosed arteries, bypass grafts, and arteriovenous fistulas. J Vasc Surg 1985; 2:406-414.
22. Risius B, Graor RA, Geisinger MA, et al. Recombinant human tissue-type plasminogen activator for thrombolysis in peripheral arteries and bypass grafts. Radiology 1986; 160:183-188.
23. Graor RA, Risius B, Lucas RV, et al. Thrombolysis with recombinant human tissue-type plasminogen activator in patients with peripheral artery and bypass graft occlusions. Circulation 1986; 74(suppI):I-15.
24. Risius B, Graor RA, Geisenger MA, et al. Thrombolytic therapy with recombinant human tissue-type plasminogen activator: a comparison of two doses. Radiology 1987; 164: 465-468.
25. Krupski WC, Feldman RK, Rapp JH. Recombinant human tissue-type plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: preliminary report. J Vasc Surg 1989; 10:491-498.
26. Decrinis M, Pilger E, Stark G, et al. A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results. Eur Heart J 1993; 14:297-305.
27. Ward AZ, Andaz SK, Bygrave S. Peripheral thrombolysis with tissue plasminogen activator: results of two treatment regimens. Arch Surg 1994; 129:861-865.
28. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19:1021-1030.
29. Weaver FA, Comerota AJ, Youngblood M, et al. Surgical revascularization versus thrombolysis for non-embolic lower extremity native artery occlusions: results of a prospective randomized trial. J Vasc Surg 1996; 24:513-523.
30. Comerota AJ, Weaver FA, Hosking JD, et al. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg 1996; 172:105-112.
31. The STILE investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. Ann Surg 1994; 220:251-268.
32. Ouriel K, Veith FJ, Sasahara AA for the TOPAS investigators. Thrombolysis or peripheral arterial surgery: Phase I results. J Vasc Surg 1996; 23:64-75.
33. Oriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998; 338:1105-1111.
34. Huettl EA, Soulen MC. Thrombolysis of lower extremity embolie occlusions: a study of the results of the STAR registry. Radiology 1995; 197:141-145.